Metformin protects ovarian granulosa cells in chemotherapy-induced premature ovarian failure mice through AMPK/PPAR-γ/SIRT1 pathway Original paper
Researched by:
-
Divine Aleru
ID
Divine Aleru
Read MoreI am a biochemist with a deep curiosity for the human microbiome and how it shapes human health, and I enjoy making microbiome science more accessible through research and writing. With 2 years experience in microbiome research, I have curated microbiome studies, analyzed microbial signatures, and now focus on interventions as a Microbiome Signatures and Interventions Research Coordinator.
-
Women’s Health
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
-
Primary Ovarian Insufficiency (POI)
Primary Ovarian Insufficiency (POI)
Primary Ovarian Insufficiency (POI) is a medical condition in which a woman’s ovaries stop functioning normally before the age of 40. This leads to reduced estrogen production and irregular menstrual cycles, which may eventually result in infertility and early menopause-like symptoms. POI can occur due to various reasons, including genetic factors, autoimmune disorders, chemotherapy, or unknown causes. Though often misunderstood and misdiagnosed, POI can significantly impact a woman's physical and emotional well-being. Early diagnosis and appropriate treatment, including hormone replacement therapy (HRT) and fertility interventions, can help manage symptoms, improve quality of life, and in some cases, restore fertility.
-
Divine Aleru
Read More
Researched by:
-
Divine Aleru
ID
Divine Aleru
Read More
Microbiome Signatures identifies and validates condition-specific microbiome shifts and interventions to accelerate clinical translation. Our multidisciplinary team supports clinicians, researchers, and innovators in turning microbiome science into actionable medicine.
Divine Aleru
What was studied?
This study investigates the protective effects of metformin (MET) on ovarian granulosa cells (GCs) in chemotherapy-induced premature ovarian failure (POF) mice. The research explores the therapeutic potential of MET, known for its anti-inflammatory and antioxidant properties, in mitigating the ovarian damage caused by chemotherapy agents such as cyclophosphamide (CTX) and busulfan (BUS). The study specifically examines the role of MET in reducing inflammation, oxidative stress, and senescence in GCs, ultimately aiming to protect ovarian function and improve reproductive outcomes in POF.
Who was studied?
The study used a chemotherapy-induced POF mouse model, where female mice (6-7 weeks old) were injected with cyclophosphamide and busulfan to induce ovarian dysfunction. These mice were then treated with MET to evaluate its protective effects. The study also involved primary ovarian granulosa cells (GCs) co-cultured with M1 macrophages to simulate inflammatory conditions observed in POF. This model was used to assess the molecular mechanisms underlying MET’s effects on ovarian health, specifically focusing on the AMPK/PPAR-γ/SIRT1 signaling pathway.
Most important findings
The study found that MET administration significantly improved ovarian health in chemotherapy-induced POF mice. MET treatment led to an increase in ovarian weight and follicular development, alongside improvements in estrous cycle regularity and hormonal balance, as evidenced by increased estradiol (E2) and decreased follicle-stimulating hormone (FSH) levels. The study also demonstrated that MET alleviated oxidative stress by upregulating antioxidant enzyme activities and reduced inflammation by inhibiting M1 macrophage polarization and pro-inflammatory cytokine production. In cell culture experiments, MET mitigated the damage to GCs induced by M1 macrophages, reducing ROS accumulation and cellular senescence. Furthermore, the protective effects of MET were linked to the activation of the AMPK/PPAR-γ/SIRT1 pathway, highlighting its role in enhancing cellular homeostasis and preventing follicular atresia.
Key implications
This study provides compelling evidence for the use of MET as a potential therapeutic intervention for POF, particularly in patients with chemotherapy-induced ovarian damage. By targeting inflammation and oxidative stress, MET may offer a novel approach to preserving ovarian function and fertility in women affected by POF. The activation of the AMPK/PPAR-γ/SIRT1 pathway could serve as a key mechanism for MET’s protective effects, suggesting that similar pathways might be targeted in clinical treatments for ovarian insufficiency. Further research, particularly clinical trials, is needed to confirm the applicability of these findings in human patients.
Metformin
Metformin is a synthetic derivative of guanidine derived from the guanidine alkaloid of the plant Galega officinalis L. with significant hypoglycemic effects. It is a first-line antihyperglycemic agent due to its efficacy, low cost, and favorable safety profile.
Primary Ovarian Insufficiency (POI)
Primary Ovarian Insufficiency (POI) is a medical condition in which a woman’s ovaries stop functioning normally before the age of 40. This leads to reduced estrogen production and irregular menstrual cycles, which may eventually result in infertility and early menopause-like symptoms. POI can occur due to various reasons, including genetic factors, autoimmune disorders, chemotherapy, or unknown causes. Though often misunderstood and misdiagnosed, POI can significantly impact a woman's physical and emotional well-being. Early diagnosis and appropriate treatment, including hormone replacement therapy (HRT) and fertility interventions, can help manage symptoms, improve quality of life, and in some cases, restore fertility.